About Azora Therapeutics
Azora Therapeutics is a company based in Los Angeles (United States) founded in 2019 by Matt Davidson.. Azora Therapeutics has raised $581.45 thousand across 1 funding round. Azora Therapeutics offers products and services including AT177 and AT193. Azora Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Los Angeles, United States
- Founders Matt Davidson
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Azora Therapeutics Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$581.45 K (USD)
in 1 rounds
-
Latest Funding Round
$581.45 K (USD), Seed
Aug 08, 2023
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Azora Therapeutics
Azora Therapeutics offers a comprehensive portfolio of products and services, including AT177 and AT193. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational small molecule for autoimmune diseases treatment
Investigational therapy for serious inflammatory conditions
Unlock access to complete
Unlock access to complete
Funding Insights of Azora Therapeutics
Azora Therapeutics has successfully raised a total of $581.45K through 1 strategic funding round. The most recent funding activity was a Seed round of $581.45 thousand completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $581,449
-
First Round
First Round
(08 Aug 2023)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Seed - Azora Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Azora Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Azora Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Azora Therapeutics Comparisons
Competitors of Azora Therapeutics
Azora Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for allergic and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Azora Therapeutics
When was Azora Therapeutics founded?
Azora Therapeutics was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Where is Azora Therapeutics located?
Azora Therapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Who is the current CEO of Azora Therapeutics?
Matt Davidson is the current CEO of Azora Therapeutics. They have also founded this company.
Is Azora Therapeutics a funded company?
Azora Therapeutics is a funded company, having raised a total of $581.45K across 1 funding round to date. The company's 1st funding round was a Seed of $581.45K, raised on Aug 08, 2023.
What does Azora Therapeutics do?
Azora Therapeutics was founded in 2019 in Los Angeles, United States, within the biotechnology sector. Small molecule formulations are developed to activate the AhR pathway in the skin and colon, aiming to modulate immune responses for inflammatory conditions. Operations center on advancing treatments for diseases such as Hidradenitis Suppurativa, nail psoriasis, and ulcerative colitis, with AT-193 as the primary candidate under evaluation.
Who are the top competitors of Azora Therapeutics?
Azora Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
What products or services does Azora Therapeutics offer?
Azora Therapeutics offers AT177 and AT193.